WORCESTER, Mass. and TORONTO, Oct. 21, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that its wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has issued a white paper outlining the advantages of its Ii-Key technology in the development of an effective Ebola vaccine.
Antigen Express has a proprietary technology platform focused on specific activation of critical components of the immune system. As purely synthetic means are employed, more rapid development of new vaccines, at a lower cost, and with fewer manufacturing obstacles than traditional vaccines, is possible. The Antigen Express vaccines can be generated quickly to meet the demands of new threats, with one of the most recent threats being the Ebola virus.
- The severity of the recent Ebola outbreak and failure of the health care system to contain the infection rates in West Africa underscore the need for the development of an effective vaccine that can be readily deployed in the field.
- A vaccine is needed to best protect the healthcare workers and volunteers caring for Ebola patients, who are at the highest risk of infection, especially those operating in underequipped field conditions.
- Experimental studies with Ebola virus vaccines have highlighted the need for efficient CD4+ T cell responses during immunization to yield an effective vaccine.
- The Antigen Express Ii-Key Hybrid technology specifically and efficiently activates CD4+ T cell responses and is capable of both stimulating efficient immune responses on its own as well as boosting the efficacy of other vaccines to generate more robust humoral and cellular immunity.
- Ii-Key Hybrids have been shown to be safe, well-tolerated, and to generate the desired specific immune response in humans in Phase I and II cancer vaccine trials as well as in a Phase I trial of Ii-Key hybrid vaccines targeted to the H5N1 (avian) and H1N1 (swine) influenza strains.
The white paper, which can be viewed online at the Generex and Antigen Express websites, presents the advantages of Antigen Express technology in development of an Ebola vaccine. In particular, this is presented in the context of the specific immunopathology of Ebola virus infection and its ability to resist the immune system. The specific advantages of Antigen Express technology for development of a protective Ebola virus vaccine for use in third world countries where the virus is endemic as well as developed countries is presented.
Antigen Express has an active partnering program for its lead products in breast and prostate cancer. It is also seeking strategic partners for its rapid vaccine development platform.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/generex-announces-publication-of-ebola-vaccine-white-paper-by-antigen-express-916439190.html
SOURCE Generex Biotechnology Corporation
Help employers find you! Check out all the jobs and post your resume.
